A retrospective study on the clinical characteristics and prognosis of alopecia totalis and universalis: An update on prognosis

J Dermatol. 2023 Oct;50(10):1335-1338. doi: 10.1111/1346-8138.16840. Epub 2023 May 19.

Abstract

Alopecia totalis (AT) and alopecia universalis (AU) is known to have a poor prognosis with high relapse rate, and treatment failure is observed in most patients, regardless of the type of therapy. Although treatment and the prognosis of AT and AU have improved in recent years, old data are routinely cited in recent review papers without questioning them. The authors aimed to study the clinical characteristics and prognosis of AT and AU to update and compare the results with those of previously reported studies. The authors retrospectively reviewed patients diagnosed with AT and AU from 2006 to 2017 in a single institution. Of the 419 patients, the mean age at first episode was 22.9 years, and 24.6% had early onset (≤13 years). During follow-up, 53.9% had more than 50% hair growth, and 19.6% of patients showed >90% hair growth. Among patients who showed >50% improvement, 36.7% had no recurrence. In early studies conducted in the 1950s and 1960s, the chance of full hair regrowth was reported to be <10%. In our study, patients with >90% improvement in AT and AU accounted for 19.6% of patients. The authors provide an update on data regarding the prognoses of AT and AU.

Keywords: alopecia areata; alopecia universalis; prognosis.

MeSH terms

  • Alopecia / drug therapy
  • Alopecia / therapy
  • Alopecia Areata* / drug therapy
  • Hair
  • Humans
  • Prognosis
  • Retrospective Studies

Supplementary concepts

  • Alopecia universalis